leisure time -WSS

leisure time

author：entertainment 2025-08-24 05:25:12 - browse：7821

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： FDA panel to weigh approval of NurOwn, controversial ALS drug

WSS

Biotech stock slump in 2023: awaiting the turnaround

Change Healthcare cyberattack prompts Medicare loan program

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Emergency workers more likely to restrain Black patients: study

Intarcia’s device

The problem with charging patients to message their doctors

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

EpiPen alternative approval delay highlights citizen petition issue

Walensky prepares to leave CDC — and Congress — behind

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

EpiPen alternative approval delay highlights citizen petition issue

Trump demands the U.S. pay no more for drugs than other countries … again

CDC advisers recommend seasonal use of Pfizer RSV shot

Tori Bowie and the unacceptable rates of Black maternal death

Changes to biosimilar regulatory framework must prioritize patients

explore

Just how do doctors, lawmakers, and the public define abortion?

Second xenotransplant done with gene

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

Air quality improving but still lags in Black, Hispanic communities

How to bring more disabled researchers into academia

Senators: Long

leisure time

leisure time

entertainment

hotspot